How can we ensure public return on public investment?: Access to medicines in the context of COVID19
Date/Time
Date(s) - 23/06/2020
11:00 CEST - 12:00 CEST
Categories No Categories
Missed the live event? Watch the recorded broadcast here.
Public Return on Public Investment – Zugang zu Arzneimitteln im Kontext der Corona-Pandemie
Vor dem Hintergrund der COVID19-Pandemie gewinnt das Thema Zugang zu lebenswichtigenArzneimitteln und öffentlich geförderten medizinischen Innovationen an besonderer Relevanz.Health Action International (HAI) und Universities Allied for Essential Medicines (UAEM) Europe ladendeshalb zu einem öffentlichen Webinar ein, das alternative Modelle der Innovationsverwertung innerhalbund jenseits des oft dysfuktionalen auf Patentanreizen basierendem System diskutieren will. Die TeilnehmerInnen werden unter anderem folgende Fragen diskutieren:- Wird die aktuelle Pandemie ein neues Verständnis von Wissensmanagement und einesozialverträgliche Nutzung von Innovationen hervorbringen?- Welche Auswirkungen wird die Reform des Infektionsschutzgesetzes vom März 2020 auf Patente undöffentlich finanzierte Forschung in Deutschland haben?- Ist Lizenzierung das richtige Instrument, um die Lücke zwischen öffentlicher Forschung und demZugang zu Endprodukten wie Arzneimitteln zu schließen?mit- Dr. Victoria Chege, Dozentin für Europäisches Wirtschaftsrecht,Carl von Ossietzky Universität Oldenburg- Prof. Dr. Christine Godt, Professorin für Europäisches undInternationales Wirtschaftsrecht, Carl von Ossietzky UniversitätOldenburg- Paul Schnase, Universities Allied for Essential Medicines- Jaume Vidal, Senior Politikberater, Health Action International- Dr. Christian Wagner-Ahlfs, Experte Equitable Licensing
Geplaatst door Health Action International op Dinsdag 23 juni 2020
Health Action International (HAI) and Universities Allied for Essential Medicines (UAEM) Europe will host an online discussion on the need for new ways to harness innovation and promote access to medicines within and beyond the current market oriented, patent-centred model.
In the context of the challenges exacerbated by the COVID-19 pandemic, we will look at the latest developments in Europe, with specific focus on Germany, while considering the resources included in HAI’s publication “Guidelines for Socially Responsible Management of Innovation”.
For the last decade, Germany has witnessed an animated debate between academics, advocates and policy makers around how best to articulate public-generated knowledge and industrial policies, including the development and manufacturing of medicines. This discussion is gaining new traction with the occurrence of shortages of medicines and the need to respond to a health crisis.
As a leading player in the European Union (EU) health policy debate and as the country about to take up the Presidency of the European Council, Germany can make a strong case for a socially responsible response to COVID-19, as well as to other obstacles affecting access to medicines.
This discussion will bring together a diverse audience to exchange ideas on the importance of access to innovation in Germany, and the wider EU, grounding the debate in the responsibility of government, public authorities, universities and public research institutions to ensure public return on public investment.
Please find more information and register at bit.ly/publicreturn_corona.
Please note: The event will be held in German and English. Unfortunately, we can’t provide translation.